Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral THC:CBD Cannabis Extract for Chemotherapy-Induced Nausea and Vomiting
TCTR20220829003Phase 0Recruiting
- Sponsor
- Bhumibol Adulyadej Hospital
- Start
- Dec 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 0, randomised, double-blind trial of nabiximols in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Bhumibol Adulyadej Hospital. Started Dec 2021; status: recruiting.
02
Drugs
nabiximols
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on TCTR20220829003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220829003.